MA59661B1 - Conjugués de médicament anticorps comprenant des dérivés d'ectéinascidine - Google Patents
Conjugués de médicament anticorps comprenant des dérivés d'ectéinascidineInfo
- Publication number
- MA59661B1 MA59661B1 MA59661A MA59661A MA59661B1 MA 59661 B1 MA59661 B1 MA 59661B1 MA 59661 A MA59661 A MA 59661A MA 59661 A MA59661 A MA 59661A MA 59661 B1 MA59661 B1 MA 59661B1
- Authority
- MA
- Morocco
- Prior art keywords
- drug conjugates
- antibody drug
- ecteinascidin
- derivatives
- applicable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382759 | 2018-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59661B1 true MA59661B1 (fr) | 2023-03-31 |
Family
ID=64426824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59661A MA59661B1 (fr) | 2018-10-25 | 2019-10-25 | Conjugués de médicament anticorps comprenant des dérivés d'ectéinascidine |
Country Status (37)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102491180B1 (ko) * | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| IL308389A (en) * | 2021-05-19 | 2024-01-01 | Pharma Mar Sa | Dosing regimens for acubactadine |
| KR102625740B1 (ko) * | 2021-07-15 | 2024-01-17 | 주식회사 새한비엠 | 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재 |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| AU2024210894A1 (en) * | 2023-01-17 | 2025-07-17 | Adcytherix Sas | Ecteinascidin derivative antibody drug conjugates |
| WO2024186263A1 (en) | 2023-03-07 | 2024-09-12 | Axcynsis Therapeutics Pte. Ltd. | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |
| CN118878690B (zh) * | 2023-11-28 | 2026-01-09 | 南京大学 | 一种抗地高辛纳米抗体的制备及其应用 |
| TW202547489A (zh) * | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 |
| TW202547488A (zh) * | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合 |
| WO2025233522A1 (en) * | 2024-05-10 | 2025-11-13 | Pharma Mar, S.A. | Synthetic process for an ecteinascidin |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| AR035842A1 (es) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| GB0119243D0 (en) | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| KR20070053214A (ko) * | 2004-08-26 | 2007-05-23 | 니콜라스 피라말 인디아 리미티드 | 신규 생분해성 링커를 함유하는 프로드럭 |
| JP4993645B2 (ja) | 2004-12-01 | 2012-08-08 | ジェネンテック， インコーポレイテッド | 抗体薬剤結合体および方法 |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| GB201506405D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| KR102491180B1 (ko) * | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| CN115427081B (zh) * | 2020-04-21 | 2025-12-09 | 法马马有限公司 | 药物抗体共轭物 |
-
2019
- 2019-10-23 TW TW108138205A patent/TWI824043B/zh active
- 2019-10-24 AR ARP190103069A patent/AR117657A1/es unknown
- 2019-10-25 RS RS20230219A patent/RS64068B1/sr unknown
- 2019-10-25 ES ES19790550T patent/ES2939494T3/es active Active
- 2019-10-25 HR HRP20230275TT patent/HRP20230275T1/hr unknown
- 2019-10-25 MY MYPI2021002234A patent/MY206221A/en unknown
- 2019-10-25 UA UAA202102699A patent/UA129803C2/uk unknown
- 2019-10-25 DK DK19790550.8T patent/DK3870234T3/da active
- 2019-10-25 LT LTEPPCT/EP2019/079188T patent/LT3870234T/lt unknown
- 2019-10-25 WO PCT/EP2019/079188 patent/WO2020084115A1/en not_active Ceased
- 2019-10-25 PL PL19790550.8T patent/PL3870234T3/pl unknown
- 2019-10-25 SM SM20230076T patent/SMT202300076T1/it unknown
- 2019-10-25 CN CN201980084790.7A patent/CN113226377B/zh active Active
- 2019-10-25 SG SG11202104154WA patent/SG11202104154WA/en unknown
- 2019-10-25 IL IL282577A patent/IL282577B2/en unknown
- 2019-10-25 HU HUE19790550A patent/HUE061606T2/hu unknown
- 2019-10-25 FI FIEP19790550.8T patent/FI3870234T3/fi active
- 2019-10-25 AU AU2019368687A patent/AU2019368687B2/en active Active
- 2019-10-25 EP EP19790550.8A patent/EP3870234B1/en active Active
- 2019-10-25 MA MA59661A patent/MA59661B1/fr unknown
- 2019-10-25 SI SI201930466T patent/SI3870234T1/sl unknown
- 2019-10-25 PT PT197905508T patent/PT3870234T/pt unknown
- 2019-10-25 US US17/288,567 patent/US20230012681A1/en active Pending
- 2019-10-25 EA EA202191131A patent/EA202191131A1/ru unknown
- 2019-10-25 CA CA3117268A patent/CA3117268C/en active Active
- 2019-10-25 KR KR1020217015900A patent/KR20210086669A/ko active Pending
- 2019-10-25 MD MDE20210819T patent/MD3870234T2/ro unknown
- 2019-10-25 BR BR112021007718-9A patent/BR112021007718A2/pt unknown
- 2019-10-25 JP JP2021523064A patent/JP7629400B2/ja active Active
- 2019-10-25 MX MX2021004746A patent/MX2021004746A/es unknown
-
2021
- 2021-04-22 CL CL2021001039A patent/CL2021001039A1/es unknown
- 2021-04-23 PH PH12021550930A patent/PH12021550930A1/en unknown
- 2021-04-25 JO JOJO/P/2021/0083A patent/JOP20210083B1/ar active
- 2021-04-25 SA SA521421855A patent/SA521421855B1/ar unknown
- 2021-05-20 EC ECSENADI202135414A patent/ECSP21035414A/es unknown
- 2021-05-21 ZA ZA2021/03478A patent/ZA202103478B/en unknown
- 2021-05-24 CO CONC2021/0006838A patent/CO2021006838A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA59661B1 (fr) | Conjugués de médicament anticorps comprenant des dérivés d'ectéinascidine | |
| Ogitani et al. | Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology | |
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| EA202192137A1 (ru) | Конъюгат аматоксинового аналога с разветвленными линкерами | |
| EP3854418A4 (en) | TREATMENT OF HER3 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE | |
| JP7117797B2 (ja) | プラチナ薬剤の毒性の予防方法 | |
| MA38647B1 (fr) | Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x | |
| MA30226B1 (fr) | Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique. | |
| EA202190471A1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| EA199700267A1 (ru) | Применение фумагиллола и его производных для приготовления антиинфекционных интестинальных препаратов и фармацевтическая композиция на их основе | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| MA27129A1 (fr) | Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine. | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| JOP20220265A1 (ar) | مترافقات عقار- جسم مضاد | |
| EP3804764A4 (en) | TREATMENT OF HER2 MUTANT CANCER BY ADMINISTRATION OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | |
| WO2018187574A1 (en) | Compositions and methods for the treatment of fungal infections | |
| BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
| JOP20250076A1 (ar) | طرق لعلاج السرطان باستخدام مشتقات أيزو كوينولين أو 6-آزا-كوينولين | |
| EA201070352A1 (ru) | 1- или 2-замещённые производные артемизинина для повышения in vivo биологической активности биологически активных соединений | |
| JP7104424B2 (ja) | 相乗的に抗菌効力及び耐久性を改善するポケット再設計バンコマイシン類似体への末梢修飾 | |
| WO2024220546A3 (en) | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates | |
| JP2023522104A (ja) | グアニジン修飾ｃ末端バンコマイシン化合物、組成物及び方法 | |
| CO2024017369A2 (es) | Derivados de bisaminotiol funcionalizados, complejos con estos derivados de bisaminotiol y uso de dichos complejos como agentes diagnósticos y terapéuticos |